Montreal classification
Patients escalated to anti-TNFα therapy | Patients successfully treated LDTA for 1 year | ||||
---|---|---|---|---|---|
Age | M/F | Montreal classification | Age | M/F | Montreal classification |
59 | M | A3L2B1 | 66 | M | A3L2B1 |
70 | F | A3L2B1 | 55 | F | A3L3B1 |
33 | F | A2L3B1 | 39 | F | A2L2B1 |
23 | F | A2L3B3 | 48 | M | A2L2B1 |
27 | F | A2L3B1p | 44 | F | A2L3B2 |
34 | F | A1L2B1 | 28 | F | A2L3B1p |
36 | M | A2L1B3 | 65 | F | A3L1B2 |
66 | F | A3L3B1 | 43 | M | A2L1B3 |
85 | M | A2L3B3 | 49 | M | A3L2B1 |
35 | F | A2L3B3 | 60 | M | A3L1B1 |
60 | M | A3L2B1 | 35 | F | A1L3B1 |
28 | F | A2L1B2 | 72 | M | A3L2B1 |
66 | M | A3L3B1 | |||
67 | M | A3L2B1 |
Sex, p=0.267 (Fisher's exact).
Montreal classification: A (p=0.609), L (p=0.879), B (p=0.609) (Fisher’s exact).
Age, p=0.359 (Student's t test).
LDTA, low dose thiopurine and allopurinol.